The University of Chicago Header Logo

Connection

Everett E. Vokes to Neoplasms

Back to Details
This is a "connection" page, showing publications Everett E. Vokes has written about Neoplasms.
Everett E. Vokes
Connection Strength
0.932
Neoplasms
  1. 2022 Presidential Address: Advancing Equitable Cancer Care Through Innovation. J Clin Oncol. 2022 09 01; 40(25):2859-2862.
    View in: PubMed
    Score: 0.298
  2. The concurrent chemoradiation paradigm--general principles. Nat Clin Pract Oncol. 2007 Feb; 4(2):86-100.
    View in: PubMed
    Score: 0.102
  3. Phase I Study of Stereotactic Body Radiotherapy plus Nivolumab and Urelumab or Cabiralizumab in Advanced Solid Tumors. Clin Cancer Res. 2021 10 15; 27(20):5510-5518.
    View in: PubMed
    Score: 0.069
  4. All-trans retinoic acid overcomes solid tumor radioresistance by inducing inflammatory macrophages. Sci Immunol. 2021 06 15; 6(60).
    View in: PubMed
    Score: 0.069
  5. Radiotherapy and immunotherapy converge on elimination of tumor-promoting erythroid progenitor cells through adaptive immunity. Sci Transl Med. 2021 02 24; 13(582).
    View in: PubMed
    Score: 0.068
  6. Efficacy and safety results of depatuxizumab mafodotin (ABT-414) in patients with advanced solid tumors likely to overexpress epidermal growth factor receptor. Cancer. 2018 05 15; 124(10):2174-2183.
    View in: PubMed
    Score: 0.055
  7. Effects of vascular endothelial growth factor signaling inhibition on human erythropoiesis. Oncologist. 2013; 18(8):965-70.
    View in: PubMed
    Score: 0.040
  8. Differences in clinical trial patient attributes and outcomes according to enrollment setting. J Clin Oncol. 2010 Jan 10; 28(2):215-21.
    View in: PubMed
    Score: 0.031
  9. Expression and mutational analysis of MET in human solid cancers. Genes Chromosomes Cancer. 2008 Dec; 47(12):1025-37.
    View in: PubMed
    Score: 0.029
  10. An initial report of a radiation dose-escalation trial in patients with one to five sites of metastatic disease. Clin Cancer Res. 2008 Aug 15; 14(16):5255-9.
    View in: PubMed
    Score: 0.028
  11. The cancer and leukemia group B respiratory committee. Clin Cancer Res. 2006 Jun 01; 12(11 Pt 2):3581s-8s.
    View in: PubMed
    Score: 0.024
  12. Irinogenetics: what is the right star? J Clin Oncol. 2006 May 20; 24(15):2221-4.
    View in: PubMed
    Score: 0.024
  13. Clinical Cancer Advances 2005: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology. J Clin Oncol. 2006 Jan 01; 24(1):190-205.
    View in: PubMed
    Score: 0.024
  14. Recommended guidelines for the treatment of cancer treatment-induced diarrhea. J Clin Oncol. 2004 Jul 15; 22(14):2918-26.
    View in: PubMed
    Score: 0.021
  15. Dose-ranging study of the safety and pharmacokinetics of atrasentan in patients with refractory malignancies. Clin Cancer Res. 2004 Jul 01; 10(13):4406-11.
    View in: PubMed
    Score: 0.021
  16. A phase I study of suramin with once- or twice-monthly dosing in patients with advanced cancer. Cancer Chemother Pharmacol. 2002 Jul; 50(1):1-5.
    View in: PubMed
    Score: 0.018
  17. PAX5 is expressed in small-cell lung cancer and positively regulates c-Met transcription. Lab Invest. 2009 Mar; 89(3):301-14.
    View in: PubMed
    Score: 0.007
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.